Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

Status: Completed
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subjects must read, understand and sign the Statement of Informed Consent

• Subjects must be at least 18 years of age

• Subjects must be habitual soft contact lens (CL) wearers, with a daily, weekly, bi- weekly or monthly replacement schedule

• Habitual contact lenses must have a suitable fit as determined by the investigator

• Subjects must report a history of dry eye symptoms, for which they have used rewetting drops or Artificial Tears (ATs) in the past 30 days

• Subjects must be willing to discontinue the use of Artificial Tears (ATs) and rewetting drops for the duration of the study

• Subjects must have a score of 12 or higher on the CLDEQ (Contact Lens Dry Eye Questionnaire-8) at baseline

• Subjects must have at least 2 of the following signs of dry eye disease:

∙ High tear osmolarity \> 308 mOsm/L, (milliosmoles per liter) or a difference greater than 8 mOsm/L between eyes

‣ Any corneal staining

‣ Any bulbar conjunctival staining

‣ Low TBUT (tear break up time) (\<10s)

‣ Schirmer \<10mm in either eye

• Subjects must be able to read at least half of the 20/25 (via entrance Snellen visual acuity) or better in each eye in their current contact lens prescription.

⁃ Subjects currently wearing reusable contact lenses must be willing to use Clear Care solution for cleaning and disinfecting throughout the study.

Locations
United States
New York
State University of New York College of Optometry Clinical Vision Research Center
New York
Time Frame
Start Date: 2022-09-22
Completion Date: 2023-05-15
Participants
Target number of participants: 32
Treatments
Placebo_comparator: Lifitegrast Ophthalmic Solution Vehicle
Experimental: Lifitegrast Ophthalmic Solution 5%
Sponsors
Collaborators: Novartis Pharmaceuticals, Bausch & Lomb Incorporated
Leads: State University of New York College of Optometry

This content was sourced from clinicaltrials.gov